RE:ONCY presents 2 posters at ASCO 2024
“The two abstracts that we are sharing at ASCO this year are in synch with our mission of advancing pelareorep towards registrational trials"
https://www.financialnewsmedia.com/news-oncy/
1. Advancing to Registrational Study in HR+/HER2- mBC - Breast Cancer Registrational Trial Update Planned for H1 2024 - 2 year OS data milestone at end of May 2024
2. Registrational Plan in Pancreatic Cancer Driven by Promising GOBLET Phase 1/2 Data & Supported by FDA Fast Track Designation - An ORR of 62% was observed, representing a near tripling from historical controls; 7.2 mo mPFS, 10.6 mo interim mOS are ≥25% compared to historical control trials - Translational data from GOBLET show that patients with increases in blood TILs showed a decrease in tumor volumes
https://oncolyticsbiotech.com/wp-content/uploads/2024/05/Oncolytics_Deck-May_v4.pdf